On December 27, 2023 TAE Life Sciences reported that it is set to unveil significant strides in its innovative drug development at the esteemed Biotech Showcase, taking place in parallel to the 42nd annual J.P. Morgan Healthcare Conference (JPM) (Press release, TAE Life Sciences, DEC 27, 2023, View Source [SID1234638808]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the event, Rob Hill, Chief Executive Officer of TAE Life Sciences, will unveil groundbreaking insights derived from recent studies on BTS, the company’s proprietary boronated drug designed for Boron Neutron Capture Therapy (BNCT). Mr. Hill’s presentation will delve into pivotal findings, shedding light on the potential of BTS to revolutionize the treatment landscape for cancer patients. This development holds significant promise for BNCT—a highly precise and targeted radiation therapy applicable to various cancer types. The study results not only contribute to advancing medical knowledge but also open new avenues for enhancing the effectiveness of cancer treatment through cutting-edge applications.
Moreover, Hill will shed light on TAE’s patent-pending Fc-engineered antibodies, heralding a new era in site-specific conjugation and reduced effector function. These antibodies, meticulously engineered with mutations in the CH2 domain, enable precise site-specific conjugation while silencing the Fc region. This breakthrough technology holds immense promise for both Antibody Boron Conjugates (ABC) for BNCT applications and Antibody Drug Conjugates (ADC), presenting a versatile approach in the landscape of oncology therapeutics.
"Our commitment to pioneering advancements in antibody therapies is underscored by our latest breakthroughs in BTS and Fc-engineered antibodies," stated Rob Hill, CEO of TAE Life Sciences. "We’re excited about the potential impact these developments hold for targeted cancer treatments, offering new possibilities for precision medicine."
Details about Rob Hill’s presentation at Biotech Showcase 2024:
Date: January 8, 2024
Time: 2:45 PM
Location: Biotech Showcase 2024; Hilton San Francisco, Yosemite C (Ballroom Level)
TAE Life Sciences invites interested stakeholders and investors to attend Rob’s presentation to gain deeper insights into these transformative developments and explore potential collaborations.
To schedule a meeting with Rob Hill at Biotech Showcase or JPM, please contact Anna Theriault at [email protected].
For more information about TAE Life Sciences, BTS, engineered antibody drugs, and Alphabeam BNCT system, please visit www.taelifesciences.com.